Jiangsu Hengrui Medicine Past Earnings Performance
Past criteria checks 4/6
Jiangsu Hengrui Medicine's earnings have been declining at an average annual rate of -5.9%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 0.08% per year. Jiangsu Hengrui Medicine's return on equity is 10.4%, and it has net margins of 19%.
Key information
-5.9%
Earnings growth rate
-5.9%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -0.08% |
Return on equity | 10.4% |
Net Margin | 19.0% |
Next Earnings Update | 22 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Jiangsu Hengrui Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 23,325 | 4,432 | 10,120 | 5,025 |
31 Dec 23 | 22,820 | 4,302 | 9,978 | 4,954 |
30 Sep 23 | 22,344 | 4,207 | 10,120 | 5,115 |
30 Jun 23 | 22,216 | 4,095 | 10,144 | 5,034 |
31 Mar 23 | 21,289 | 3,909 | 9,559 | 5,028 |
31 Dec 22 | 21,275 | 3,906 | 9,680 | 4,887 |
30 Sep 22 | 21,652 | 3,496 | 10,327 | 5,299 |
30 Jun 22 | 22,836 | 3,982 | 10,664 | 5,547 |
31 Mar 22 | 24,455 | 4,271 | 11,588 | 5,634 |
31 Dec 21 | 25,906 | 4,530 | 12,240 | 5,943 |
30 Sep 21 | 28,520 | 6,277 | 12,635 | 5,787 |
30 Jun 21 | 29,723 | 6,334 | 13,660 | 5,706 |
31 Mar 21 | 29,137 | 6,510 | 13,428 | 5,494 |
31 Dec 20 | 27,735 | 6,328 | 12,879 | 4,989 |
30 Sep 20 | 25,757 | 5,852 | 11,904 | 4,341 |
30 Jun 20 | 24,571 | 5,577 | 11,332 | 4,276 |
31 Mar 20 | 23,849 | 5,451 | 10,996 | 4,046 |
31 Dec 19 | 23,289 | 5,328 | 10,784 | 3,896 |
30 Sep 19 | 21,904 | 4,889 | 10,156 | 3,833 |
30 Jun 19 | 19,683 | 4,568 | 9,174 | 3,159 |
31 Mar 19 | 18,528 | 4,309 | 8,566 | 2,910 |
31 Dec 18 | 17,418 | 4,066 | 8,113 | 2,670 |
30 Sep 18 | 16,228 | 3,801 | 7,456 | 2,252 |
30 Jun 18 | 15,252 | 3,553 | 6,289 | 2,754 |
31 Mar 18 | 14,523 | 3,354 | 6,406 | 2,181 |
31 Dec 17 | 13,836 | 3,217 | 6,396 | 1,759 |
30 Sep 17 | 12,896 | 2,988 | 6,329 | 1,243 |
30 Jun 17 | 12,159 | 2,848 | 7,165 | 0 |
31 Mar 17 | 11,594 | 2,716 | 6,910 | 0 |
31 Dec 16 | 11,094 | 2,589 | 6,615 | 0 |
30 Sep 16 | 10,709 | 2,529 | 6,320 | 0 |
30 Jun 16 | 10,209 | 2,425 | 5,998 | 0 |
31 Mar 16 | 9,781 | 2,309 | 5,668 | 0 |
31 Dec 15 | 9,316 | 2,172 | 5,361 | 0 |
30 Sep 15 | 8,833 | 1,970 | 5,101 | 0 |
30 Jun 15 | 8,328 | 1,817 | 4,786 | 0 |
31 Mar 15 | 7,935 | 1,673 | 4,551 | 0 |
31 Dec 14 | 7,452 | 1,516 | 4,301 | 0 |
30 Sep 14 | 7,156 | 1,429 | 4,170 | 0 |
30 Jun 14 | 6,744 | 1,356 | 3,871 | 0 |
31 Mar 14 | 6,443 | 1,292 | 3,600 | 0 |
31 Dec 13 | 6,203 | 1,238 | 3,501 | 0 |
30 Sep 13 | 5,933 | 1,199 | 3,237 | 0 |
Quality Earnings: 600276 has high quality earnings.
Growing Profit Margin: 600276's current net profit margins (19%) are higher than last year (18.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600276's earnings have declined by 5.9% per year over the past 5 years.
Accelerating Growth: 600276's earnings growth over the past year (13.4%) exceeds its 5-year average (-5.9% per year).
Earnings vs Industry: 600276 earnings growth over the past year (13.4%) exceeded the Pharmaceuticals industry -0.8%.
Return on Equity
High ROE: 600276's Return on Equity (10.4%) is considered low.